Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lixte Biotechnology Holdings (LIXT) Common Equity (2016)

Lixte Biotechnology Holdings' Common Equity history spans 7 years, with the latest figure at $737984.0 for Q3 2016.

  • For Q3 2016, Common Equity fell 8.31% year-over-year to $737984.0; the TTM value through Sep 2016 reached $737984.0, down 8.31%, while the annual FY2015 figure was $312333.0, N/A changed from the prior year.
  • Common Equity reached $737984.0 in Q3 2016 per LIXT's latest filing, down from $1.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.9 million in Q2 2012 to a low of -$265550.0 in Q1 2012.
  • Average Common Equity over 5 years is $894696.9, with a median of $926851.0 recorded in 2013.
  • Peak YoY movement for Common Equity: skyrocketed 1787.93% in 2012, then crashed 107.96% in 2014.
  • A 5-year view of Common Equity shows it stood at $1.5 million in 2012, then plummeted by 84.16% to $236266.0 in 2013, then soared by 151.35% to $593851.0 in 2014, then crashed by 47.41% to $312333.0 in 2015, then skyrocketed by 136.28% to $737984.0 in 2016.
  • Per Business Quant, the three most recent readings for LIXT's Common Equity are $737984.0 (Q3 2016), $1.2 million (Q2 2016), and $1.0 million (Q1 2016).